SPOTLIGHT: J&J chops jobs


With Procrit under siege, Johnson & Johnson wants to divert its promotional efforts elsewhere--a strategy that will lead to some 400 job cuts in its sales-and-marketing ranks. The company told employees it would consolidate sales-and-marketing operations of Ortho Biotech and Centocor and shave the payroll accordingly. Layoff report

Suggested Articles

The patient was hospitalized with febrile neutropenia in the weeks after receiving the drug and died 52 days post-treatment with the CAR-T therapy.

The trial has been paused since early September while FDA reviews the safety of the vaccine in light of a reported case of an inflammatory disorder.

Biogen is cutting its experimental multiple sclerosis drug opicinumab as well as an spinal muscular atrophy candidate amid a third-quarter clear-out.